Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: A prospective phase 2 single-arm trial.
Eur J Nucl Med Mol ImagingJun 8, 2026 (epub)
Jian Pan, Beihe Wang, Bin Zhu et al.
✦ AI-curated · Sources linked
In 30 seconds
The CHAMPION trial, a multicenter phase II study, evaluated the efficacy of consolidative therapy for PSMA-avid lesions in 48 newly diagnosed metastatic hormone-sensitive prostate cancer patients with ≤10 distant metastases after three cycles of apalutamide. The study found a high undetectable PSA rate of 95.8% after six cycles, indicating effective treatment response.
Key findings
- The undetectable PSA rate increased from 66.7% after three cycles to 95.8% after six cycles.
- Distant lymph node metastases had the highest response rate at 93.3%.
- Only 4.2% of patients experienced grade ≥3 rash as an adverse event.
Why it matters
This study highlights a promising treatment strategy for patients with limited metastatic burden, potentially improving outcomes in a challenging subset of metastatic hormone-sensitive prostate cancer.